Search

Your search keyword '"Heidenreich, Axel"' showing total 2,943 results
Start Over Author "Heidenreich, Axel"
2,943 results on '"Heidenreich, Axel"'

9. Uro-Onkologie

Author

Girtner, Florian Alois, additional, Mayr, Roman, additional, Gall, Gregor, additional, Gakis, Georgios, additional, Kälble, Sebastian, additional, Spachmann, Philipp, additional, Roesch, Marie Christine, additional, Matzen, Merle, additional, Manka, Lukas, additional, Hammerer, Peter, additional, and Heidenreich, Axel, additional

Published
2024
Full Text
View/download PDF

11. Safety and Efficacy of 177Lu-PSMA Therapy Following 223Radium Treatment: A Retrospective Multinational Real-World Analysis

Author

Giannini, Giulia, Kafka, Mona, Neuwirt, Hannes, Artamonova, Nastasiia, Santo, Gianpaolo di, Virgolini, Irene, Dotzauer, Robert, Deiss, Emil, Paffenholz, Pia, Heidenreich, Axel, Rasul, Sazan, Tsaur, Igor, Rausch, Steffen, Einspieler, Holger, la Fougère, Christian, Trautwein, Nils F., Zattoni, Fabio, Sepulcri, Matteo, and Heidegger, Isabel

Published
2025
Full Text
View/download PDF

13. Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database

Author

Lauritsen, Jakob, Sauvé, Nicolas, Tryakin, Alexey, Jiang, Di Maria, Huddart, Robert, Heng, Daniel Y. C., Terbuch, Angelika, Winquist, Eric, Chovanec, Michal, Hentrich, Marcus, Fankhauser, Christian D., Shamash, Jonathan, del Muro, Xavier Garcia, Vaughn, David, Heidenreich, Axel, Sternberg, Cora N., Sweeney, Christopher, Necchi, Andrea, Bokemeyer, Carsten, Bandak, Mikkel, Jandari, Abolghassem, Collette, Laurence, Gillessen, Silke, Beyer, Joerg, and Daugaard, Gedske

Published
2023
Full Text
View/download PDF

16. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study

Author

Rajwa, Pawel, Robesti, Daniele, Chaloupka, Michael, Zattoni, Fabio, Giesen, Alexander, Huebner, Nicolai A., Krzywon, Aleksandra, Miszczyk, Marcin, Moll, Matthias, Stando, Rafał, Cisero, Edoardo, Semko, Sofiya, Checcucci, Enrico, Devos, Gaëtan, Apfelbeck, Maria, Gatti, Cecilia, Marra, Giancarlo, van den Bergh, Roderick C.N., Goldner, Gregor, Rasul, Sazan, Ceci, Francesco, Dal Moro, Fabrizio, Porpiglia, Francesco, Gontero, Paolo, Bjartell, Anders, Stief, Christian, Heidenreich, Axel, Joniau, Steven, Briganti, Alberto, Shariat, Shahrokh F., and Gandaglia, Giorgio

Published
2024
Full Text
View/download PDF

17. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Author

Kafka, Mona, Horninger, Andreas, di Santo, Gianpaolo, Virgolini, Irene, Neuwirt, Hannes, Unterrainer, Lena M., Kunte, Sophie C., Deiss, Emil, Paffenholz, Pia, Heidenreich, Axel, Rasul, Sazan, Einspieler, Holger, Shariat, Shahrokh F., Rajwa, Pawel, Dozauer, Robert, Tsaur, Igor, Medlock, Ellen, Rölz, Niklas, Rausch, Steffen, la Fougère, Christian, Trautwein, Nils, Roesch, Marie C., Merseburger, Axel S., Zattoni, Fabio, Sepulcri, Matteo, Ladurner, Michael, Bektic, Jasmin, Gandaglia, Giorgio, Horninger, Wolfgang, and Heidegger, Isabel

Published
2024
Full Text
View/download PDF

19. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

Author

Bührer, Emanuel, D'Haese, David, Daugaard, Gedske, de Wit, Ronald, Albany, Costantine, Tryakin, Alexey, Fizazi, Karim, Stahl, Olof, Gietema, Jourik A., De Giorgi, Ugo, Cafferty, Fay H., Hansen, Aaron R., Tandstad, Torgrim, Huddart, Robert A., Necchi, Andrea, Sweeney, Christopher J., Garcia-Del-Muro, Xavier, Heng, Daniel Y.C., Lorch, Anja, Chovanec, Michal, Winquist, Eric, Grimison, Peter, Feldman, Darren R., Terbuch, Angelika, Hentrich, Marcus, Bokemeyer, Carsten, Negaard, Helene, Fankhauser, Christian, Shamash, Jonathan, Vaughn, David J., Sternberg, Cora N., Heidenreich, Axel, Collette, Laurence, Gillessen, Silke, and Beyer, Jörg

Published
2024
Full Text
View/download PDF

21. Therapie des metastasierten Hodentumors

Author

Pfister, David, Schmelz, Hans, Heidenreich, Axel, Schrader, Mark, Section editor, Michel, Maurice Stephan, editor, W. Thüroff, Joachim, editor, Janetschek, Günter, editor, and Wirth, Manfred P., editor

Published
2023
Full Text
View/download PDF

27. An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading

Author

Tolkach, Yuri, Ovtcharov, Vlado, Pryalukhin, Alexey, Eich, Marie-Lisa, Gaisa, Nadine Therese, Braun, Martin, Radzhabov, Abdukhamid, Quaas, Alexander, Hammerer, Peter, Dellmann, Ansgar, Hulla, Wolfgang, Haffner, Michael C., Reis, Henning, Fahoum, Ibrahim, Samarska, Iryna, Borbat, Artem, Pham, Hoa, Heidenreich, Axel, Klein, Sebastian, Netto, George, Caie, Peter, and Buettner, Reinhard

Published
2023
Full Text
View/download PDF

29. Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care?

Author

Hugar, Lee A., Peak, Taylor C., Naqvi, Mahrukh, Kim, Youngchul, Bandini, Marco, Pederzoli, Filippo, Marandino, Laura, Albersen, Maarten, Roussel, Eduard, Zhu, Yao, Ye, Ding-Wei, Ornellas, Antonio A., Catanzaro, Mario, Hakenberg, Oliver W., Heidenreich, Axel, Haidl, Friederike, Watkin, Nick, Ager, Michael, Briganti, Alberto, Salvioni, Roberto, Chakiryan, Nicholas H., Montorsi, Francesco, Necchi, Andrea, and Spiess, Philippe E.

Published
2023
Full Text
View/download PDF

30. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

Author

Abida, Wassim, Campbell, David, Patnaik, Akash, Bryce, Alan H., Shapiro, Jeremy, Bambury, Richard M., Zhang, Jingsong, Burke, John M., Castellano, Daniel, Font, Albert, Ganju, Vinod, Hardy-Bessard, Anne-Claire, McDermott, Ray, Sautois, Brieuc, Spaeth, Dominique, Voog, Eric, Piulats, Josep M., Pintus, Elias, Ryan, Charles J., Merseburger, Axel S., Daugaard, Gedske, Heidenreich, Axel, Fizazi, Karim, Loehr, Andrea, Despain, Darrin, Simmons, Andrew D., Dowson, Melanie, Go, Jowell, Watkins, Simon P., and Chowdhury, Simon

Published
2023
Full Text
View/download PDF

31. European Association of Urology Guidelines on Testicular Cancer: 2023 Update

Author

Patrikidou, Anna, Cazzaniga, Walter, Berney, Daniel, Boormans, Joost, de Angst, Isabel, Di Nardo, Domenico, Fankhauser, Christian, Fischer, Stefanie, Gravina, Carmen, Gremmels, Hendrik, Heidenreich, Axel, Janisch, Florian, Leão, Ricardo, Nicolai, Nicola, Oing, Christoph, Oldenburg, Jan, Shepherd, Robert, Tandstad, Torgrim, and Nicol, David

Published
2023
Full Text
View/download PDF

32. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Author

Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Chi, Kim N, Clarke, Noel, Davis, Ian D, de Bono, Johann, Drake, Charles G, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Heinrich, Daniel, Higano, Celestia Tia S, Hofman, Michael S, Hussain, Maha, James, Nicolas, Kanesvaran, Ravindran, Kantoff, Philip, Khauli, Raja B, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Chris, Poon, Darren MC, Pritchard, Colin C, Reiter, Robert E, Roach, Mack, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Small, Eric, Smith, Matthew, Soule, Howard, Sternberg, Cora N, Steuber, Thomas, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tombal, Bertrand, Türkeri, Levent, van Oort, Inge, Zapatero, Almudena, and Omlin, Aurelius

Subjects
Cancer, Urologic Diseases, Aging, Prostate Cancer, Good Health and Well Being, Bone Neoplasms, Humans, Male, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging, Practice Guidelines as Topic, Prostate-Specific Antigen, Prostatic Neoplasms, Advanced prostate cancer, High-risk localised prostate cancer, Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Oligometastatic prostate cancer, Progression-free survival, Overall survival, Prostate cancer treatment, Imaging, Genetics, Tumour genomic profiling, Castration-naïve prostate cancer, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.ObjectiveTo present the results from the APCCC 2019.Design, setting, and participantsSimilar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions.Outcome measurements and statistical analysisThe panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process.Results and limitationsPanellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material.ConclusionsThese voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials.Patient summaryThe Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.

Published
2020

36. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study

Author

Antonelli, Luca, Ardizzone, Davide, Ravi, Praful, Bagrodia, Aditya, Mego, Michal, Daneshmand, Siamak, Nicolai, Nicola, Nazzani, Sebastiano, Giannatempo, Patrizia, Franza, Andrea, Heidenreich, Axel, Paffenholz, Pia, Saoud, Ragheed, Eggener, Scott, Ho, Matthew, Oswald, Nathaniel, Olson, Kathleen, Tryakin, Alexey, Fedyanin, Mikhail, Naoun, Natacha, Javaud, Christophe, Fizazi, Karim, King, Jennifer M., Adra, Nabil, Douglawi, Antoin, Cary, Clint, Sweeney, Christopher, and Fankhauser, Christian D.

Published
2023
Full Text
View/download PDF

39. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

Author

Heidegger, Isabel, Resch, Johannes Mischinger Irene, Turba, Simon, Zeder, Robin, Lodeta, Braninimir, Van Praet, Charles, Ghysel, Christophe, Arentsen, Harm C., Beysens, Matthias, Vinckier, Marie-Hélène, Mottrie, Alexandre, de Groote, Ruben, Timev, Aleksandar Ivanov, Georgiev, Marincho Ivanov, Yanev, Krassimir Prodanov, Mladenov, Boris, Ivanov, Atanas Slavchev, Antonov, Petar, Valkanov, Stanislav, Tomašković, Igor, Kulis, Tomislav, Bokarica, Pero, Pavlović, Oliver, Krajina, Vinko, Situm, Marijan, Boban, Toni, Soric, Tomislav, Vidic, Ivan, Benko, Goran, Peršec, Zoran, Sović, Tomislav, Zachoval, Roman, Stejskal, Jiri, Capoun, Otakar, Pitra, Tomáš, Gojdič, Marek, Babjuk, Marek, Novák, Vojtěch, Grepl, Michal, Broul, Marek, Novák, Jan, Lund, Lars, Nordström Joensen, Ulla, Borre, Michael, Veskimäe, Priit, Baum, Peep, Tamm, Toomas, Okas, Rauno, Jämsä, Pyry, Lahdensuo, Kanerva, Siltari, Sirkku, Seikkula, Heikki, Palmberg, Christian, Isotalo, Taina, Fiard, Gaelle, Verrier, Cecile, Wiedemann, Laura, Lecornet, Emilie, Leon, Priscilla, Millet, Clementine, Ponzio, Charles, Ploussard, Guillaume, Xylinas, Evanguelos, Ingels, Alexandre, Bigot, Pierre, Le Corre, Vincent, Audenet, François, Berg, Sebastian, Palisaar, Rein-Jueri, Heidenreich, Axel, Seelemeyer, Felix, Krege, Susanne, Leyh-Bannurah, Sami-Ramzi, Witt, Jörn H., Abdirahman, Ayanle, Truß, Michael C., Kranz, Jennifer, Andreas, Karagiannis, Vassileios, Tzortzis, Andreas, Andreou, Paparidis, Spyridon, Davis, Nikolaos Ferakis Niall F., Keane, Kevin G., Fuentes, Adrian, Scuderi, Simone, Barletta, Francesco, Manfredi, Matteo, Porpiglia, Francesco, Cerruto, Maria Angela, Antonelli, Alessandro, Esperto, Francesco, Rossanese, Marta, Veneziano, Domenico, Castelli, Tommaso, Mantica, Roberto La Rocca Marcello Scarcia Guglielmo, Rebuffo, Silvia, Pomara, Giorgio, Pavan, Nicola, Silvestri, Tommaso, Reale, Giulio Francesco, Polara, Andrea, Falagario, Ugo Giovanni, Carrieri, Giuseppe, Ferrari, Giovanni, Brausi, Maurizio, Orecchia, Luca, Annino, Filippo, Kazlauskas, Gražvydas, Stavridis, Sotir, Radovic, Nenad, Vukovic, Marko, van der Slot, Margaretha Adriana, Bruins, Harman Maxim, van Oort, Inge, Witjes, Fred, van der Poel, Henk, Beisland, Christian, Lilleåsenm, Gunder, Müller, Stig, Haug, Erik S., Dimmen, Magne, Czech, Anna K., Nyk, Lukasz, Jaskulski, Jaroslaw, Ratajczyk, Krzysztof, Azevedo, Nuno, Braga, Isaac, Pereira, João, Lúcio, Rui, Pina, João, da Silva, Edgar Miguel Calvo Loureiro Tavares, Furriel, Frederico, Mota, Paulo, Rodrigues, Miguel, Radavoi, George Daniel, Crisan, Nicolae, Andras, Iulia, Robert, Stoica, Bratu, Ovidiu, Surcel, Cristian, Kotov, Sergei, Malkhasyan, Vigen, Petrov, Sergei, Reva, Sergei, Bumbasirevic, Uros, Kováčik, Viktor, Perečinský, Ivan, Rybár, Ľuboš, Šulgan, Ján, Briš, Lukáš, Jursová, Katarína, Chovan, Miroslav, Kička, Tomáš, Taskovska, Milena, Kovačič, Rok, Miklavžina, Andraž, Alvarez-Maestro, Mario, De Castro, Javier Mayor, Aragón-Chamizo, Juan, Sutil, Raquel Sopeña, Perrello, Carmen Garau, Vilaseca, Antoni, Perez, Jorge Huguet, Ovide, Julia Aumatell, Planas, Jacques, Borque-Fernando, Angel, Sánchez-Izquierdo, Elena, Jimenez, Jose Luis Marenco, Lendínez-Cano, Guillermo, Puche-Sanz, Ignacio, Garcia-Baquero, Rodrigo, Esteban, Mario Domínguez, Pérez-Fentes, Daniel, Serván, Patricia Parra, Koskela, Lotta Renström, Stranne, Johan, Scholtz, Bianca, Torbrand, Christian, Wagenius, Magnus, Ugge, Henrik, Örtegren, Joakim, Langenauer, Janine, Zumstein, Valentin, Schmid, Hans Peter, Rieken, Malte, Saba, Karim, Strebel, Raeto T., Mortezavi, Ashkan, Rentsch, Cyrill, Roth, Beat, Eberli, Daniel, Pascal, Oechslin, Auer, Rebecca, John, Hubert, Thalmann, George N., Baltacı, Sümer, Mungan, Aydın, Sözen, Sinan, Cetin, Serhat, Aslan, Guven, Türkeri, Levent, İzol, Volkan, Demirdağ, Çetin, Ozden, Sami Berk, Toktaş, Gökhan, Sarikaya, Şaban, Tinay, İlker, Müezzinoğlu, Talha, Erbatu, Oguzcan, Sagnak, Levent, Akdoğan, Bülent, Can, Cavit, Şahin, Hayrettin, Yazıcı, Cenk Murat, Volkov, Serhii, Shulyak, Olexandr, Douglas, David, Hemmant, Joshua, El-Taji, Omar, Ahmad, Imran, Nalagatla, Sarika, Janebdar, Husay, Veeratterapillay, Rajan, Rai, Bhavan, Conroy, Samantha, Cumberbatch, Marcus, Malde, Sachin, MacLennan, Steven, Duncan, Eilidh, Dunsmore, Jennifer, Fullwood, Louise, Lumen, Nicolaas, Plass, Karin, Ribal, Maria J., Roobol, Monique J., Nieboer, Daan, Schouten, Natasha, Skolarus, Ted A., Smith, Emma Jane, N'Dow, James, Mottet, Nicolas, and Briganti, Alberto

Published
2023
Full Text
View/download PDF

43. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Author

Terbuch, Angelika, Posch, Florian, Bauernhofer, Thomas, Jost, Philipp J., Partl, Richard, Stranzl-Lawatsch, Heidi, Baciarello, Giulia, Fizazi, Karim, Giannatempo, Patrizia, Verzoni, Elena, Sweeney, Christopher, Ravi, Praful, Tran, Ben, Basso, Umberto, White, Jeff, Vincenzi, Bruno, Oing, Christoph, Cutuli, Hernan Javier, Dieckmann, Klaus Peter, Gamulin, Marija, Chovanec, Michal, Fankhauser, Christian Daniel, Heidenreich, Axel, Mohamad, Osama, Thibault, Constance, Fischer, Stefanie, and Gillessen, Silke

Published
2022
Full Text
View/download PDF

45. Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery

Author

Huebner, Nicolai, Rasul, Sazan, Baltzer, Pascal, Clauser, Paola, Hermann Grubmüller, Karl, Mitterhauser, Markus, Hacker, Marcus, Heidenreich, Axel, Rajwa, Pawel, Fajkovic, Harun, Shariat, Shahrokh F., and Grubmüller, Bernhard

Published
2022
Full Text
View/download PDF

46. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy

Author

Bravi, Carlo A., Droghetti, Matteo, Fossati, Nicola, Gandaglia, Giorgio, Suardi, Nazareno, Mazzone, Elio, Cucchiara, Vito, Scuderi, Simone, Barletta, Francesco, Schiavina, Riccardo, Osmonov, Daniar, Juenemann, Klaus-Peter, Boeri, Luca, Karnes, R. Jeffrey, Kretschmer, Alexander, Buchner, Alexander, Stief, Christian, Hiester, Andreas, Nini, Alessandro, Albers, Peter, Devos, Gaëtan, Joniau, Steven, Van Poppel, Hendrik, Grubmüller, Bernhard, Shariat, Shahrokh F., Heidenreich, Axel, Pfister, David, Tilki, Derya, Graefen, Markus, Gill, Inderbir S., Mottrie, Alexandre, Karakiewicz, Pierre I., Montorsi, Francesco, and Briganti, Alberto

Published
2022
Full Text
View/download PDF

48. Trophoblast cell surface antigen‐2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma.

Author

Weiten, Richard, Storz, Enno, Kessler, Carolina, Sperber, Laurenz, Spohn, Hanna Elisa, Pfister, David, Nestler, Tim, Tolkach, Yuri, Linden, Friederike, Wirtz, Ralph, von Brandenstein, Melanie, Krausewitz, Philipp, and Heidenreich, Axel

Subjects
IMMUNOSTAINING, SQUAMOUS cell carcinoma, LYMPHATIC metastasis, GENE expression, BLOOD proteins
Abstract

Objective: To evaluate the potential utility of antibody‐drug conjugates targeting trophoblast cell surface antigen‐2 (TROP‐2) in patients with primary penile squamous cell carcinoma (PSCC), patients with recurrence (REC cohort), and patient‐matched distant metastases (MET cohort), and to assess the potential use of TROP‐2 as a predictive non‐invasive biomarker in PSCC. Methods: A cohort comprising a PRIM (n = 37), REC (n = 5) and MET subcohort (n = 7), with MET including lymph node and lung metastases, was analysed using quantitative real‐time PCR, ELISA and immunohistochemical staining with evaluation of H‐score. Results: TROP‐2 mRNA and serum protein levels were significantly increased in primary and recurrent PSCC compared to cancer‐free controls (both P < 0.001). Immunohistochemical analysis revealed that most of the PRIM cohort (n = 34/37, median H‐score 260, interquartile range [IQR] 210–300), as well as all patients in the REC (median [IQR] H‐score 200 [165–290]) and MET cohorts (median [IQR] H‐score 280 [260–300]) exhibited moderate to strong membranous TROP‐2 expression. Additionally, The H‐score (membranous TROP‐2 expression) was positively correlated with TROP‐2 mRNA (ρ = 0.69, P < 0.0001, R2 = 0.70) and protein levels (ρ = 0.86, P < 0.0001, R2 = 0.59), indicating its potential as a non‐invasive biomarker in PSCC. Conclusion: In summary, our results support further studies on TROP‐2 as a diagnostic and therapeutic target in primary, recurrent and metastatic PSCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Cost‐effectiveness analysis of different treatment modalities in BCG‐unresponsive NMIBC.

Author

Rieger, Constantin, Schlüchtermann, Jörg, Storz, Enno, Kastner, Lucas, Pfister, David, and Heidenreich, Axel

Subjects
MONTE Carlo method, SALVAGE therapy, MARKOV processes, DOCETAXEL, PEMBROLIZUMAB
Abstract

Objective: Radical cystectomy (RC) is the standard of care (SOC) in BCG‐unresponsive NMIBC and is associated with a significant health‐related quality‐of‐life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost‐Effectiveness‐Analysis of those treatment modalities. Patients and Methods: We developed a Markov model from a payer's perspective drawing on clinical data of single‐arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG‐unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC (n = 29) as intravesical salvage chemotherapy at our uro‐oncological centre in Cologne. Costs were simulated utilising a non‐commercial diagnosis‐related groups grouper, utilities were derived from comparable cost‐effectiveness studies. We used a Monte Carlo simulation to identify the optimal treatment, comparing the incremental cost effectiveness ratios (ICERs) at a willingness‐to‐pay threshold of €50 000 (euro)/quality‐adjusted life year (QALY). Results: Over a horizon of 10 years, gemcitabine/docetaxel, HIVEC, and pembrolizumab were associated with costs of €48 353, €64 438, and €204 580, as well as a gain of QALYs of 6.16, 6.48, and 6.00, resulting in an ICER of €26 482, €42 567, and €184 533 respectively, in comparison to RC with total costs of €21 871 and a gain of QALYs of 5.01. Monte Carlo simulation identified HIVEC as the treatment of choice under assumption of a WTP of <€50 000. Conclusion: Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost‐effective therapeutic options in BCG‐refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost‐effective assuming a price reduction of at least 70%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Preservation of the native urethral plate and corpus spongiosum combined with buccal mucosa graft plus Orandi's penile skin flap as an alternative to staged urethroplasty for narrow penile strictures.

Author

Karapanos, Leonidas, Halbe, Luisa, Storz, Enno, Rieger, Constantin, Weiten, Richard, Ergashev, Bobirjon, and Heidenreich, Axel

Subjects
URETHRA stricture, URINARY diversion, DIVERTICULUM, URETHROPLASTY, MUCOUS membranes, CORPORA
Abstract

Objective: In narrow anterior urethral strictures, the combined buccal mucosa graft (BMG) with pedicled penile skin flap (PSF) represents a well‐known effective alternative to staged urethroplasty. We hypothesized that if the native urethral plate and adjacent corpus spongiosum were preserved, a narrower flap would be needed, and reinforced ventral stability could be achieved without compromising the surgical outcome. Methods: Twelve patients with narrow penile urethral strictures underwent single‐stage augmentation urethroplasty using a combined technique. A BMG was quilted to the corpora cavernosa in a dorsal onlay approach, and a longitudinal ventral PSF was transposed ventrally and sutured to the scarred native urethral mucosa on one side and to the BMG on the other side to form a neourethra of triangular form. The preserved corpus spongiosum was wrapped and fixed around the flap ventrally. Results: The median age was 47 years (IQR 35–59), and the median stricture length was 5 cm (IQR 3, 8–7). The median surgical time was 205 min (IQR 172–236). The overall success rate (SR) was 91.7% without sacculation or diverticula formation after a median follow‐up period of 38 months (IQR 33–40). Three transient fistulas healed through prolonged urinary diversion. Five patients (41.7%) reported postvoid dribbling following urethroplasty. Conclusion: Preservation of the native urethral plate is a valuable adjunct to the combination of graft and flap for single‐stage augmentation urethroplasty for narrow urethral strictures, with satisfactory mid‐term success and an acceptable complication rate. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results